Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk

ABSTRACT: The CHOlesterol Reduction and Residual Risk in type 2 Diabetes (CHORD) study was a prospective study that investigated the effect of lipid lowering therapieis in participants with LDL-C >100 mg/dL without cardiovascular disease, off all antiplatelet therapy. Individuals with MPA levels, defined as CD14+CD16+ cells, were measured before and after four weeks of lipid lowering therapy. Patients were categorized as MPAhigh or MPAlow based on consistently high or low MPA levels accross timepoints. MPAhigh individuals exhibited an enrichment of immune signaling pathway. We developed a 42/gene Thromboinflammation Platelet Signature (TIPS), which correlated with MPA levels in multiple cohorts. TIPS was significantly elevated in patients with COVID-19 and myocardial infarction and predicted future cardiovascular events in patients who underwent lower extremity revascularization after a median follow-up of 18 months. Notably, TIPS was modifiable by ticagrelor. These findings introduce TIPS as a novel platelet RNA signature that captures platelet-immune activity and offers a promising tool for cardiovascular risk stratification.

ORGANISM(S): Homo sapiens

PROVIDER: GSE308951 | GEO | 2025/10/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk

Project description:A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk

| PRJNA1333481 | ENA

Platelets impair the resolution of inflammation in atherosclerotic plaques in insulin-resistant mice after lipid-lowering

Project description:Insulin resistance reduces the benefits of lipid-lowering, as evidenced by higher cardiovascular risk in type 2 diabetes despite LDL-cholesterol reduction. Platelet activation, a key feature in insulin resistance, may hinder inflammation resolution in atherosclerosis. Using an obese, insulin-resistant mouse model, we induced atherosclerosis and treated mice with an apoprotein B oligonucleotide for lipid-lowering, with or without platelet depletion. Platelet depletion increased Fcgr4+ macrophages, reduced necrotic cores, and dampened inflammatory gene expression. Platelets hinder inflammation resolution in insulin resistance during lipid-lowering. Targeting platelet activity may enhance atherosclerosis regression and reduce cardiovascular risk.

2025-09-05 | GSE286091 | GEO

Inhibiting the P2Y12 Receptor in Megakaryocytes and Platelets Suppresses Interferon-Associated Responses

Project description:Megakaryocytes (MKs) and platelets are recognized mediators of inflammation and altered immunity. While antiplatelet therapies are widely used to prevent cardiovascular events, their role in attenuating platelet-mediated inflammation is uncertain. This study was designed to investigate the transcriptomic effect of APT on MKs and its impact on proinflammatory pathways. We demonstrated a significant effect on the MK transcriptome following P2Y12 receptor inhibition. Specifically, we found a significant downregulation of IFN pathways with P2Y12 receptor inhibition. In conclusion, targeting the P2Y12 receptor modulates MK and platelet inflammatory signaling pathways. P2Y12-mediated suppression of MK IFNα signaling may benefit proinflammatory diseases

2025-05-07 | GSE242369 | GEO

Fibrin drives thromboinflammation and neuropathology in COVID-19 [NK_Fibrin_in_vitro]

Project description:Life-threatening thrombotic events and neurological symptoms are prevalent in COVID-19 and are persistent in patients with long COVID experiencing post-acute sequelae of SARS-CoV-2 infection1,2,3,4. Despite the clinical evidence1,5,6,7, the underlying mechanisms of coagulopathy in COVID-19 and its consequences in inflammation and neuropathology remain poorly understood and treatment options are insufficient. Fibrinogen, the central structural component of blood clots, is abundantly deposited in the lungs and brains of patients with COVID-19, correlates with disease severity and is a predictive biomarker for post-COVID-19 cognitive deficits1,5,8,9,10. Here we show that fibrin binds to the SARS-CoV-2 spike protein, forming proinflammatory blood clots that drive systemic thromboinflammation and neuropathology in COVID-19. Fibrin, acting through its inflammatory domain, is required for oxidative stress and macrophage activation in the lungs, whereas it suppresses natural killer cells, after SARS-CoV-2 infection. Fibrin promotes neuroinflammation and neuronal loss after infection, as well as innate immune activation in the brain and lungs independently of active infection. A monoclonal antibody targeting the inflammatory fibrin domain provides protection from microglial activation and neuronal injury, as well as from thromboinflammation in the lung after infection. Thus, fibrin drives inflammation and neuropathology in SARS-CoV-2 infection, and fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute COVID-19 and long COVID.

2024-06-28 | GSE268812 | GEO

Fibrin drives thromboinflammation and neuropathology in COVID-19 [Lung]

2024-06-28 | GSE268810 | GEO

Fibrin drives thromboinflammation and neuropathology in COVID-19

Project description:Fibrin drives thromboinflammation and neuropathology in COVID-19

| PRJNA1118776 | ENA

Platelet mRNA in response to antiplatelet therapy exposure

Project description:Platelet mRNA in response to antiplatelet therapy exposure

| PRJNA666442 | ENA

Fibrin drives thromboinflammation and neuropathology in COVID-19 [Lung]

Project description:Fibrin drives thromboinflammation and neuropathology in COVID-19 [Lung]

| PRJNA1118777 | ENA

Fibrin drives thromboinflammation and neuropathology in COVID-19 [NK_Fibrin_in_vitro]

Project description:Fibrin drives thromboinflammation and neuropathology in COVID-19 [NK_Fibrin_in_vitro]

| PRJNA1118782 | ENA

Expression data for pharmacogenomics antiplatelet therapy

Project description:Antiplatelet therapy is the most important treatment to reduce the risk of developing recurrent thrombosis, and to prevent progression to a complete occlusion of coronary arterial disease (CAD) patients after percutaneous coronary intervention Aim of study was to investigate the relationship between response to antiplatelet drugs and global mRNA gene expression in peripheral blood cells (PBC) in patients with coronary arterial disease (CAD) All patients were treated crhonically with acetylsalicylic acid (ASA) (100 mg/day) and clopidogrel (75 mg/day). Blood samples were drown before PCI to evaluate platelet reactivity by VerifyNowÂ® ASA and P2Y12 assays and mRNA expression was measured by Affymetrix GeneChip Human Exon 1.0 ST array.

2012-09-15 | E-GEOD-32226 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data